menu
    • menu
    [{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"BI 1701963","moa":"||MEK receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lupin Ltd \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Lupin Ltd \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Aurigene Oncology","sponsor":"Indian Council of Medical Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Aurigene Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurigene Oncology \/ Indian Council of Medical Research","highestDevelopmentStatusID":"4","companyTruncated":"Aurigene Oncology \/ Indian Council of Medical Research"},{"orgOrder":0,"company":"Aurigene","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"XL102","moa":"CDK7","graph1":"Oncology","graph2":"Preclinical","graph3":"Aurigene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aurigene \/ Exelixis","highestDevelopmentStatusID":"4","companyTruncated":"Aurigene \/ Exelixis"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Eisai","highestDevelopmentStatusID":"4","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Eisai"},{"orgOrder":0,"company":"NovoMedix","sponsor":"National Heart, Lung, And Blood Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"NMX1","moa":"mTOR","graph1":"Oncology","graph2":"Preclinical","graph3":"NovoMedix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NovoMedix \/ National Heart, Lung, And Blood Institute","highestDevelopmentStatusID":"4","companyTruncated":"NovoMedix \/ National Heart, Lung, And Blood Institute"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dr. Reddy's Laboratories

                            India
                            CPhI Korea
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Denileukin Diftitox,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Eisai

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dr. Reddy’s Laboratories Presents Preclinical Data at SITC 2020 Demonstrating Significant Improvement in Tum...

                            Details : Combination of E7777 with an anti-PD-1 agent provided clear benefit both in terms of tumor growth control, and a highly significant improvement in overall survival.

                            Product Name : E7777

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            September 11, 2020

                            Lead Product(s) : Denileukin Diftitox,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Eisai

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aurigene Oncology

                            India arrow
                            Pharmex
                            Not Confirmed

                            Aurigene Oncology

                            India arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Indian Council of Medical Research

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            ICMR partners with industry leaders for groundbreaking First-in-Human Phase-1 cl ..

                            Details : Under the partnership, ICMR will engage in collaborative research on a small molecule for multiple myeloma with Aurigene oncology.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 14, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Indian Council of Medical Research

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            NovoMedix

                            India arrow
                            Pharmex
                            Not Confirmed

                            NovoMedix

                            India arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NMX1

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : National Heart, Lung, And Blood Institute

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            NovoMedix Receives Research Grant from the National Institutes of Health (NIH) to Advance NMX1 in TBNC

                            Details : The SBIR grant will support the development of NMX1 and novel small molecules that protect Triple-Negative Breast Cancer (TNBC) patients from the devastating long-term cardiotoxic effects of doxorubicin chemotherapy.

                            Product Name : NMX1

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 26, 2022

                            Lead Product(s) : NMX1

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : National Heart, Lung, And Blood Institute

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lupin Ltd

                            India arrow
                            Pharmex
                            Not Confirmed

                            Lupin Ltd

                            India arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LNP3794,BI 1701963

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : $50.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Lupin Announces Achievement of Key Milestones for its Clinical Stage MEK Inhibitor Compound

                            Details : Lupin’s proprietary MEK inhibitor compound is planned for clinical development in combination with Boehringer Ingelheim’s KRAS inhibitor pipeline to address KRAS-driven cancers.

                            Product Name : BI 3011441

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 27, 2021

                            Lead Product(s) : LNP3794,BI 1701963

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : $50.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Aurigene

                            India arrow
                            Pharmex
                            Not Confirmed

                            Aurigene

                            India arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XL102

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Exelixis

                            Deal Size : $29.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Exelixis In-Licenses Aurigene’s CDK7 Inhibitor and Files Investigational New Drug Application for Phase 1 Tr...

                            Details : Exelixis has exercised exclusive option for Aurigene’s novel CDK7 inhibitor under the companies’ July 2019 agreement. Exelixis has now assumed responsibility for the future clinical development, commercialization, and global manufacturing of the comp...

                            Product Name : XL102

                            Product Type : Other Small Molecule

                            Upfront Cash : $10.0 million

                            July 12, 2020

                            Lead Product(s) : XL102

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Exelixis

                            Deal Size : $29.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth